Tdam USA Inc. Sells 10,091 Shares of Natus Medical Incorporated (NASDAQ:BABY)
Tdam USA Inc. reduced its position in Natus Medical Incorporated (NASDAQ:BABY) by 21.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 37,886 shares of the medical equipment provider’s stock after selling 10,091 shares during the period. Tdam USA Inc. owned 0.12% of Natus Medical worth $1,413,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently modified their holdings of BABY. Renaissance Technologies LLC boosted its position in shares of Natus Medical by 247.0% in the fourth quarter. Renaissance Technologies LLC now owns 45,800 shares of the medical equipment provider’s stock worth $1,594,000 after buying an additional 32,600 shares in the last quarter. Norges Bank bought a new position in shares of Natus Medical during the fourth quarter valued at $11,560,000. Teachers Advisors LLC boosted its position in shares of Natus Medical by 4.7% in the fourth quarter. Teachers Advisors LLC now owns 307,029 shares of the medical equipment provider’s stock valued at $10,685,000 after buying an additional 13,783 shares during the period. WCM Investment Management CA boosted its position in shares of Natus Medical by 203.1% in the first quarter. WCM Investment Management CA now owns 40,615 shares of the medical equipment provider’s stock valued at $1,594,000 after buying an additional 27,215 shares during the period. Finally, Capstone Asset Management Co. boosted its position in shares of Natus Medical by 12.5% in the first quarter. Capstone Asset Management Co. now owns 8,959 shares of the medical equipment provider’s stock valued at $352,000 after buying an additional 996 shares during the period. Institutional investors own 93.86% of the company’s stock.
Natus Medical Incorporated (NASDAQ BABY) opened at 34.55 on Tuesday. The firm’s 50-day moving average price is $36.71 and its 200 day moving average price is $36.90. Natus Medical Incorporated has a 52 week low of $33.15 and a 52 week high of $44.39. The company has a market capitalization of $1.12 billion, a PE ratio of 60.72 and a beta of 0.93.
Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The firm had revenue of $122.20 million for the quarter, compared to analysts’ expectations of $121.99 million. During the same period in the prior year, the firm posted $0.39 earnings per share. The company’s quarterly revenue was up 27.3% on a year-over-year basis. Equities research analysts expect that Natus Medical Incorporated will post $1.70 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Tdam USA Inc. Sells 10,091 Shares of Natus Medical Incorporated (NASDAQ:BABY)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/08/tdam-usa-inc-sells-10091-shares-of-natus-medical-incorporated-nasdaqbaby.html.
Several brokerages have weighed in on BABY. BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research cut Natus Medical from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Benchmark Co. restated a “buy” rating and set a $48.00 price objective (down from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Finally, TheStreet cut Natus Medical from a “b” rating to a “c+” rating in a research note on Thursday, April 27th. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. Natus Medical currently has an average rating of “Hold” and an average price target of $45.00.
In related news, insider James B. Hawkins bought 4,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were purchased at an average cost of $33.98 per share, with a total value of $135,920.00. Following the completion of the purchase, the insider now owns 578,023 shares in the company, valued at approximately $19,641,221.54. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Doris Engibous sold 5,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the completion of the sale, the director now directly owns 22,650 shares in the company, valued at $740,202. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.